- Home
- NHTC vs ANL Comparison
NHTC vs ANL Comparison
Compare NHTC & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NHTC | ANL |
|---|---|---|
| Founded | 1988 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | |
| Sector | Miscellaneous | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.3M | 52.0M |
| IPO Year | 1995 | 2023 |
Fundamental Metrics
Financial Performance| Metric | NHTC | ANL |
|---|---|---|
| Price | $2.74 | $1.05 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 73.9K | 13.6K |
| Earning Date | 11-05-2025 | 11-07-2025 |
| Dividend Yield | ★ 28.88% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $40,873,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.40 | $1.00 |
| 52 Week High | $6.00 | $2.99 |
Technical Indicators
Market Signals| Indicator | NHTC | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 38.14 | 23.81 |
| Support Level | $2.74 | $1.32 |
| Resistance Level | $3.07 | $1.59 |
| Average True Range (ATR) | 0.24 | 0.15 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 18.53 | 1.69 |
Price Performance
Historical ComparisonAbout NHTC Natural Health Trends Corp.
Natural Health Trends Corp is an international direct-selling and e-commerce company. It offers a line of products such as Wellness, Herbal, Beauty, Lifestyle, and Home. Wellness products include targeted nutrition for joint health, antioxidant support, digestive health, heart health, and vision health. Herbal products include anti-aging and hydrating cleansers, creams, lotions, serums, and toners. Lifestyle products improve the overall quality of life and to support active, physical and healthy lifestyles. Home products are designed to create a clean and natural living environment for the home. It generates a majority of its revenue from Hong Kong and rest from China, Taiwan, Japan, United States and other regions.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.